CORCEPT THERAPEUTICS INCCORTEarnings & Financial Report
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
Revenue
$146.8M
Gross Profit
$144.3M
Operating Profit
$29.5M
Net Profit
$27.8M
Gross Margin
98.3%
Operating Margin
20.1%
Net Margin
18.9%
YoY Growth
39.0%
EPS
$0.25
CORCEPT THERAPEUTICS INC Q1 FY2024 Financial Summary
CORCEPT THERAPEUTICS INC reported revenue of $146.8M (up 39.0% YoY) for Q1 FY2024, with a net profit of $27.8M (up 74.8% YoY) (18.9% margin). Cost of goods sold was $2.5M, operating expenses totaled $114.8M.
Key Financial Metrics
| Total Revenue | $146.8M |
|---|---|
| Net Profit | $27.8M |
| Gross Margin | 98.3% |
| Operating Margin | 20.1% |
| Report Period | Q1 FY2024 |
CORCEPT THERAPEUTICS INC Annual Revenue by Year
CORCEPT THERAPEUTICS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $761.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $761.4M |
| 2024 | $675.0M |
| 2023 | $482.4M |
| 2022 | $401.9M |
CORCEPT THERAPEUTICS INC Quarterly Revenue & Net Profit History
CORCEPT THERAPEUTICS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $202.1M | +11.1% | $24.3M | 12.0% |
| Q3 FY2025 | $207.6M | +13.7% | $19.7M | 9.5% |
| Q2 FY2025 | $194.4M | +18.7% | $35.1M | 18.1% |
| Q1 FY2025 | $157.2M | +7.1% | $20.5M | 13.1% |
| Q4 FY2024 | $181.9M | +34.3% | $30.7M | 16.9% |
| Q3 FY2024 | $182.5M | +47.7% | $47.2M | 25.9% |
| Q2 FY2024 | $163.8M | +39.1% | $35.5M | 21.7% |
| Q1 FY2024 | $146.8M | +39.0% | $27.8M | 18.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $146.8M | $163.8M | $182.5M | $181.9M | $157.2M | $194.4M | $207.6M | $202.1M |
| YoY Growth | 39.0% | 39.1% | 47.7% | 34.3% | 7.1% | 18.7% | 13.7% | 11.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $655.9M | $714.6M | $784.3M | $840.6M | $846.5M | $801.7M | $823.6M | $836.7M |
| Liabilities | $108.1M | $118.3M | $145.4M | $161.0M | $163.2M | $165.9M | $191.7M | $188.8M |
| Equity | $547.9M | $596.2M | $638.8M | $679.6M | $683.3M | $635.8M | $631.9M | $647.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $23.8M | $41.2M | $73.8M | $59.3M | $5.1M | $43.9M | $54.5M | $38.4M |